A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia
Cytometry Part A · 2024-03 · 105 (3) · 181-195
DOI: 10.1002/cyto.a.24811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part A, online erschienen am 08.12.2023. Verfasst von Hendrik Fokken und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, Else Kröner-Fresenius-Stiftung, Deutsche José Carreras Leukämie-Stiftung e.V..
Abstract (Originalsprache)
Multiparameter flow cytometry (MFC) has emerged as a standard method for quantifying measurable residual disease (MRD) in acute myeloid leukemia. However, the limited number of available channels on conventional flow cytometers requires the division of a diagnostic sample into several tubes, restricting the number of cells and the complexity of immunophenotypes that can be analyzed. Full spectrum flow cytometers overcome this limitation by enabling the simultaneous use of up to 40 fluorescent markers. Here, we used this approach to develop a good laboratory practice‐conform single‐tube 19‐color MRD detection assay that complies with recommendations of the European LeukemiaNet Flow‐MRD Working Party. We based our assay on clinically‐validated antibody clones and evaluated its performance on an IVD‐certified full spectrum flow cytometer. We measured MRD and normal bone marrow samples and compared the MRD data to a widely used reference MRD‐MFC panel generating highly concordant results. Using our newly developed single‐tube panel, we established reference values in healthy bone marrow for 28 consensus leukemia‐associated immunophenotypes and introduced a semi‐automated dimensionality‐reduction, clustering and cell type identification approach that aids the unbiased detection of aberrant cells. In summary, we provide a comprehensive full spectrum MRD‐MFC workflow with the potential for rapid implementation for routine diagnostics due to reduced cell requirements and ease of data analysis with increased reproducibility in comparison to conventional FlowMRD routines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Division Data Science in Biomedicine, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Braunschweig, Germany.
- Braunschweig Integrated Centre for Systems Biology (BRICS), TU Braunschweig, Braunschweig, Germany.
- Department of Orthopedic Surgery, Hannover Medical School, Hannover, Germany.
- Department of Pediatric Hematology, Hannover Medical School, Hannover, Germany.
- Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Hendrik Fokken, Adrian Schwarzer
Förderung
- Deutsche Krebshilfe
- Else Kröner-Fresenius-Stiftung
- Deutsche José Carreras Leukämie-Stiftung e.V.
- José Carreras Leukämie-Stiftung
Zitieren
APA
Fokken, H., Waclawski, J., Kattre, N., Kloos, A., Müller, S., Ettinger, M., Kacprowski, T., Heuser, M., Maetzig, T., & Schwarzer, A. (2024). A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. Cytometry Part A, 105(3), 181-195. https://doi.org/10.1002/cyto.a.24811
Vancouver
Fokken H, Waclawski J, Kattre N, Kloos A, Müller S, Ettinger M, et al. A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. Cytometry Part A. 2024;105(3):181-195. doi:10.1002/cyto.a.24811
BibTeX
@article{Fokken2024,
author = {Fokken, Hendrik and Waclawski, Julian and Kattre, Nadine and Kloos, Arnold and Müller, Sebastian and Ettinger, Max and Kacprowski, Tim and Heuser, Michael and Maetzig, Tobias and Schwarzer, Adrian},
title = {A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia},
journal = {Cytometry Part A},
year = {2024},
volume = {105},
number = {3},
pages = {181--195},
doi = {10.1002/cyto.a.24811}
}
EUVIMED